Same issue with psychedelics. However, they are so useful that people in the medical/therapeutic/academic fields are doing tons of research anyway.
Apparently big pharma is also trying to create their own psychedelics (there was an article about it on the front page of HN recently).
So far, the business seems like it will be on the assisted therapy side and everything that it entails. So more like services instead of products.
https://www.lifespan.io/campaigns/pearl-participatory-evalua...
Off topic, but whenever I think about this, I find myself thinking that what the world really needs is next-level human/medicinal modeling. Imagine if human trials didn't have to happen in order to know the long-term effects (and in a fraction of the time)!
Wouldn't they want to get treatment costs down? Large HMOs, especially, have motivation to control treatment costs, and access to the patients, data, etc... to make it work.
The key thing is more care = more dollars = more in the bank.
One response to that legislation was insurers buying care providers.
The problem is, no one wants to do those trials because rapamycin is cheap and generic. Why would Pharma spend money on something that they can't patent? Also, these kind of trials have to go on for 10+ years at a minimum - which is cost-prohibitive even if it is patentable (not to go in the weeds, but long trials count in the period of exclusivity given to pharma patents).
I believe the right approach is to use it off-label, be upfront about the potential risks, and collect lots of data so you can improve as you go. Practical anti-aging so to speak.
Another approach is through the NIH grant pathway, but that has a lot of road-blocks as well.